PRAGUE-17: Appendage Closure vs. Direct Anticoagulant Agents

After four years of follow-up, the PRAGUE-17 study showed that appendage closure is non-inferior to direct anticoagulant agents (non-warfarin oral anticoagulants, NOAC) to prevent major neurological events, cardiovascular events, and bleeding events in patients at high risk of atrial fibrillation.

PRAGUE-17: Cierre de orejuela vs anticoagulantes directos

Appendage studies were compared with warfarin studies—it was necessary to update anticoagulant agents and reach a reasonable follow-up period.

PRAGUE-17 randomized, with a non-inferiority criterion, patients who underwent appendage closure (Watchman or Amulet) vs. NOACs (apixaban in 95% of cases). These patients had experienced non-valvular atrial fibrillation and a history of cardioembolism, clinically relevant bleeding, or both (CHA2DS2-VASc > 3).

The primary endpoint was a composite of cardioembolic events (stroke, transient ischemic attack, or systemic embolism), cardiac death, clinically relevant bleeding, and device-related complications (only for the appendage closure group).

With 201 patients randomized to each group and after 3.5 years of median follow-up, appendage closure reached non-inferiority as regards the primary endpoint (pnon-inferiority = 0.0006)

Component rates (when considered separately) were similar, except for bleeding not related to the procedure. That was lower with closure devices. The bleeding risk is relevant during implantation; afterwards the risk lowers abruptly (as opposed to anticoagulant agents, with which the risk is ongoing).


Read also: CHOICE-CLOSURE | Which Closure Device for TAVR is Better?


Primary endpoint results are similar in the per protocol analysis and the per actual treatment analysis.

Conclusion

Long term follow-up of PRAGUE-17 showed that appendage closure with either of the two most popular devices is non-inferior to direct anticoagulant agents. Appendage closure devices were better in terms of bleeding not related to the procedure.

Original Title: Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17.

Reference: Pavel Osmancik et al. J Am Coll Cardiol. 2021 Oct 27; S0735-1097(21)07895-5. Online ahead of print. doi: 10.1016/j.jacc.2021.10.023. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

*

Top